Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBIT Margin (2016 - 2020)

Historic EBIT Margin for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q2 2020 value amounting to 399.06%.

  • Avadel Pharmaceuticals' EBIT Margin rose 4244100.0% to 399.06% in Q2 2020 from the same period last year, while for Mar 2021 it was 24.76%, marking a year-over-year increase of 160200.0%. This contributed to the annual value of 26.04% for FY2020, which is 667600.0% up from last year.
  • Per Avadel Pharmaceuticals' latest filing, its EBIT Margin stood at 399.06% for Q2 2020, which was up 4244100.0% from 53.07% recorded in Q1 2020.
  • Avadel Pharmaceuticals' EBIT Margin's 5-year high stood at 399.06% during Q2 2020, with a 5-year trough of 360.52% in Q4 2018.
  • Its 5-year average for EBIT Margin is 7.71%, with a median of 27.25% in 2019.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -50912500bps in 2016, then surged by 4244100bps in 2020.
  • Avadel Pharmaceuticals' EBIT Margin (Quarter) stood at 39.61% in 2016, then tumbled by -130bps to 11.74% in 2017, then plummeted by -2971bps to 360.52% in 2018, then soared by 81bps to 66.82% in 2019, then skyrocketed by 697bps to 399.06% in 2020.
  • Its last three reported values are 399.06% in Q2 2020, 53.07% for Q1 2020, and 66.82% during Q4 2019.